Cancer treatment is complex, with therapies often giving different results and causing different reactions. Regular monitoring of a patient’s health is an essential element of treatment. It also helps to detect problems such as neutropenia, a common side effect of chemotherapy, which reduces immune system function and makes cancer patients highly vulnerable to serious infections. It is estimated that such complications can lead to one in four patients being hospitalized. In this context, Entia, a healthcare technology company, has completed a successful Series A financing round of €18.7 million. The round was led by BGF and Parkwalk, as well as other existing investors. The capital was earmarked for the UK commercial launch. And for the US regulatory approval of the company’s flagship innovation Liberty (one of the most comprehensive remote patient monitoring solutions for people undergoing cancer treatment).
Providing more care to people outside the hospital is highly advantageous not only for patients, but also for healthcare providers. Such an approach allows us to move routine health assessments out of health centers. It also drives a more preventive model of healthcare, where problems are identified and addressed early. This is about improving patient care by keeping people in treatment longer, reducing unplanned hospitalizations and ultimately improving survival outcomes.Dr. Toby Basey-Fisher, CEO and Founder of Entia
Entia was founded in 2014. It works at the frontiers of remote patient monitoring and predictive analytics. It has brought together new home blood testing technology and digital solutions to deliver personalized insights into cancer patients’ journey through treatment. Currently, most monitoring is done through outpatient appointments in hospital, which can be time-consuming and costly for patients, as well as resource-intensive for healthcare providers. Entia aims to take some of these pressures off the table with Liberty. It also aims to support healthcare providers by equipping them with real-time insights that help keep treatment on track and alert them to potential complications before they impact a patient’s quality of life. Entia’s solution is unique in that it can offer symptom and vitals monitoring, as well as complete blood count analysis, including the monitoring of neutropenia, one of the most common and costly side effects of cancer treatment.
Our investment in Entia offers a profound opportunity to positively impact the lives of people with cancer. The number of people with cancer is growing. At the same time, we need to deploy and leverage innovative technologies to ensure our health systems have the resources and capacity to give everyone in need the best chance of beating this terrible disease.Neil Cameron, Investment Director at Parkwalk Advisors